Final Clinical Trial Workshop for Phase IV of the Cimavax-EGF Vaccine.

On Wednesday morning, a workshop was held at the Pharmaceutical Museum of Matanzas to analyze the final report of the Phase IV clinical trial: Safety of the Cimavax-EGF vaccine for the treatment of non-small cell lung cancer in advanced stages.

The speakers were MSc. Geidy Lorenzo Monteagudo, researcher and promoter of the Center for Molecular Immunology (CIM), and MSc. Pedro Pablo Guerra Chaviano, project manager of the National Coordinating Center for Clinical Trials (CENCEC).

During the workshop they gave presentations on the challenges and solutions from the perspective of primary care and clinical research, as well as an account of the work done and the evolution of patients in each province, according to Dr.C. Leticia Cabrera Benítez, delegate of the Center of Molecular Immunology in Matanzas.

The meeting was attended by specialists in radiology, pneumology, clinical laboratory, as well as oncologists and professionals belonging to the clinical trials department of the Comandante Faustino Pérez Clinical-Surgical Teaching Hospital, among others.

Due to the encouraging results of this clinical trial on the treatment of lung cancer for the National Health System, it was decided to make it more extensive in Cuba until reaching the current phase.

Written by Brenda González.